Zhide Guo

Title: Zhide Guo: Innovator in Nuclear Medicine and Molecular Imaging

Introduction

Zhide Guo is a prominent inventor based in Shandong, China. He has made significant contributions to the fields of nuclear medicine and molecular imaging. With a total of 2 patents, his work focuses on developing innovative compounds for medical applications.

Latest Patents

Guo's latest patents include a dual-targeting compound and a preparation method and application thereof. This compound is designed for use in nuclear medicine and molecular imaging, specifically targeting fibroblast activation protein (FAP) and integrin αβ in tumors. The dual-targeting compound demonstrates high affinity for these targets, enabling synergistic targeting in tumors, which results in high uptake and long retention time. Additionally, he has developed a truncated Evans Blue modified fibroblast activation protein inhibitor. This compound enhances the effectiveness of nuclide therapy and imaging for tumors with high expression of FAP.

Career Highlights

Zhide Guo is associated with Yantai Lannacheng Biotechnology Co., Ltd., where he continues to advance his research and development efforts. His innovative work has the potential to significantly impact the diagnosis and treatment of diseases characterized by overexpression of specific proteins.

Collaborations

Guo collaborates with notable colleagues, including Xiaoyuan Chen and Pengfei Xu, to further enhance the scope and application of his inventions.

Conclusion

Zhide Guo's contributions to nuclear medicine and molecular imaging exemplify the importance of innovation in healthcare. His patents reflect a commitment to improving medical diagnostics and therapies, showcasing the potential of targeted compounds in treating complex diseases.